Cargando…
Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems
Recently, the U.S. Food and Drug Administration (FDA) approved the first oral antiviral drug to treat mild to moderate cases of coronavirus disease. The combination of nirmatrelvir with an already used protease inhibitor class drug, ritonavir, has led to Paxlovid®. Several studies considered drug re...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585847/ https://www.ncbi.nlm.nih.gov/pubmed/36280220 http://dx.doi.org/10.1016/j.ijpharm.2022.122329 |